This brand name is authorized in Nigeria.
The drug ZITCLAV contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
Z49QDT0J8Z - CEFUROXIME AXETIL
|
|
Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
|
2
|
UNII
23521W1S24 - CLAVULANIC ACID
|
|
Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-2183 | Tablet | Zitclav DS Tablet 500 mg/125 mg TAB 500 mg; 125 mg | Each tablet contains: Cefuroxime (as Cefuroxime Axetil) 500 mg, Clavulanic Acid 125 mg | 20/12/2019 |
| B4-2422 | Powder for suspension | Zitclav Powder for Oral Suspension PWD_F_SOL 125 mg/5 mL; 31.25 mg/5 mL 60 mL | Dry Powder for Oral Suspension. Each 5 mL reconstituted suspension contains: Cefuroxime Axetil equiv. to Cefuroxime 125 mg, Clavulanic Acid 31.25 mg | 20/12/2019 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-2183, B4-2422 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.